Aimed Alliance Executive Director, Stacey Worthy, was quoted in a Bloomberg article discussing the U.S. Food and Drug Administration’s Risk Evaluation and Mitigation Strategies (REMS) program. In the article, Ms. Worthy highlights the need for REMS safeguards to give patients access to innovative brand and generic drugs that would not otherwise be available. Read the full article here.
Last Updated on May 13, 2020 by Aimed Alliance
